Navigation Links
InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
Date:3/9/2010

BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced that it will hold a webcast of a live conference call today at 5:00 p.m. EST to discuss the outcome of today's Pulmonary-Allergy Drugs Advisory Committee (PADAC).  The committee was convened by the U.S. Food and Drug Administration to review and discuss the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).  

Conference Call and Webcast Details

Investors and media may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 61659499.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 61659499.

SOURCE InterMune, Inc.

Back to top

RELATED LINKS
http://www.intermune.com

'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... DALLAS , Feb. 10, 2016  Fotona, based in ... it will launch its new ST PRO Lightwalker dental laser ... Chicago Dental Society from 25-27 February, 2016 in booth #4815. ... tissue dental laser with many of the features of the ... $49,900, the ST PRO competitive price will be very attractive ...
(Date:2/10/2016)...   Genomic Health, Inc. (Nasdaq: GHDX ) today ... ended December 31, 2015. --> --> ... compared with $69.1 million in the fourth quarter of 2014, an ... 9 percent compared with the same period in the prior year. ... $63.9 million in the fourth quarter of 2015, an increase of ...
(Date:2/10/2016)...  Cepheid (Nasdaq: CPHD ) today announced ... President and Chief Operating Officer, has been promoted ... Officer.  In his new capacity, Mr. Kocmond,s responsibilities ... Operations in addition to Manufacturing Operations, Engineering, Technical ... to report to John Bishop , Cepheid,s ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... practitioner, is known locally for a series of therapeutic sessions to help Los ... their characters and in their lives. The series, known as “Mindfulness for Actors ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop ... revolutionary new 2.0 version at the International Roofing Expo in Orlando, Florida on ... the world's most advanced weather technology in the hands of consumers, roofing contractors, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in Garland, ... the local community. Pledging to select a new beneficiary every 60 days, the ... Their goal is to bring community awareness to important local causes by forming ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):